SST and prostate cancer: These molecules tested in a non-small lung cancer cell line, and in a prostate cancer cell line showed a greater antiproliferative effect than subtype specific SST and DA agonists, alone or in combination [55, 86], and in the control of cell growth from primary cultures of human nonfunctioning pituitary adenomas [53].